Does Cigna cover Zepbound? Cigna covers Zepbound for weight loss only if your employer’s plan includes weight-loss drugs, and then with prior authorization: typically a BMI of 30 or more, or 27 or more with a weight-related condition.[1] Cigna also has a separate approval path for moderate to severe obstructive sleep apnea.[1] Employers that use Evernorth’s EncircleRx program may set stricter rules, such as a BMI of 35.[2]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
Zepbound is tirzepatide; see our tirzepatide profile.
Cigna, Express Scripts and Evernorth
Cigna’s pharmacy benefits are run by Express Scripts, part of Cigna’s Evernorth health services business. Cigna publishes the coverage policies, and Express Scripts processes the prescriptions and prior authorizations. Whether weight-loss drugs are covered at all is set by your plan document: Cigna’s policies state that a plan’s own exclusions always override its general coverage policy.[1]
Coverage by reason for treatment
| Reason prescribed | Cigna commercial | Cigna Medicare |
|---|---|---|
| Weight management | If the plan covers weight-loss drugs; prior authorization[1] | Not covered by Part D; Medicare GLP-1 Bridge for the KwikPen at $50 a month, if eligible[6] |
| Obstructive sleep apnea | Covered with prior authorization and sleep study[1] | Part D plan coverage under formulary rules[7] |
| Type 2 diabetes | Not a Zepbound use; Mounjaro is the diabetes brand[4] | Mounjaro through Part D |
| Heart risk reduction | Not a Zepbound indication[4] | Not a Zepbound indication |
Cigna’s 2026 Zepbound criteria (policy IP0816)
Cigna’s Zepbound policy, effective September 1, 2026, sets these rules.[1]
Weight management, first approval (8 months):
- Age 18 or older.
- At least 3 months of behavior changes and diet before starting.
- A starting BMI of 30 or more, or 27 or more with at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, heart disease, knee osteoarthritis, asthma, COPD, fatty liver disease or polycystic ovary syndrome.
- Used with a reduced-calorie diet and behavior changes.
“Starting BMI” means your BMI before any GLP-1 drug, so people who switch from another GLP-1 are judged on their original weight.[1]
Weight management, renewal (1 year): the same BMI rules, plus at least 5% loss of starting body weight.[1]
Obstructive sleep apnea (1 year):
- Age 18 or older and a starting BMI of 30 or more.
- A sleep study showing moderate to severe OSA with an apnea-hypopnea index or respiratory event index of 15 or more.
- No central sleep apnea or Cheyne-Stokes breathing.
- After a full year of treatment, renewal requires at least 10% loss of starting weight and stable OSA symptoms, as judged by the prescriber.[1]
The policy cites the SURMOUNT-OSA trials, in which tirzepatide cut the apnea-hypopnea index by about 20 to 24 more events per hour than placebo after 52 weeks.[1][5] See Zepbound for sleep apnea.
The EncircleRx program
EncircleRx is Evernorth’s program for employers that want to cover GLP-1 drugs for obesity, diabetes and heart disease while controlling costs. Evernorth describes it as a suite that combines clinical criteria, lifestyle programs and cost protections for plan sponsors.[3]
For Zepbound, Cigna publishes an “EncircleRx BMI 35” policy (reviewed June 17, 2026) that lets plans that otherwise exclude weight-loss drugs cover a subset of patients:[2]
- Adults with a starting BMI of 35 or more, or a BMI of 27 or more with at least two weight-related conditions.
- At least 3 months of behavior changes and diet first.
- Documentation required for each item.
Cigna states plainly that these BMI thresholds “are not based on clinical data” but are set “to allow a subset of patients” to get the drugs.[2] The policy also notes that the Zepbound KwikPen is not currently targeted in it.[2] Ask Express Scripts whether your employer uses EncircleRx and which version.
Cigna Medicare
Medicare Part D cannot cover drugs used only for weight loss. For Cigna’s Medicare drug plans:
- Sleep apnea: CMS says Zepbound prescribed for moderate to severe OSA stays under Part D, under the plan’s formulary and exception rules.[7]
- Weight management: since July 1, 2026, eligible members of most Part D and Medicare Advantage drug plans can get the Zepbound KwikPen for $50 a month through the CMS-run Medicare GLP-1 Bridge. Vials and single-dose pens are not included.[6]
See does Medicare cover Zepbound?
How to check your Cigna coverage
- Log in to myCigna or the Express Scripts app and search for Zepbound. Note the tier and any PA (prior authorization) or QL (quantity limit) flags.
- Call the member services number on your Cigna card. Ask whether weight-loss drugs are a covered benefit, whether your plan uses EncircleRx, and which policy applies.
- Ask HR about any lifestyle program your employer requires; KFF found about a third of employers that cover GLP-1s for weight loss require one.[9]
- Have your prescriber submit prior authorization with your pre-GLP-1 BMI, conditions, diet history and, for OSA, the sleep study report.
Common reasons Cigna denies Zepbound
- No weight-loss benefit. The plan document excludes weight-loss drugs, and the employer does not use EncircleRx.[1]
- Too little documented lifestyle change. Both Cigna policies require at least 3 months of behavior modification and diet before starting.[1][2]
- Only one weight-related condition under EncircleRx. The BMI 35 version needs at least two conditions if your BMI is between 27 and 35.[2]
- Using another GLP-1 at the same time. Cigna lists use with another tirzepatide product or GLP-1 drug as not medically necessary.[1]
- Central sleep apnea. People with central sleep apnea or Cheyne-Stokes breathing are not approved under the OSA pathway.[1]
If Cigna denies Zepbound
- Benefit exclusion: if your plan does not cover weight-loss drugs, ask whether EncircleRx or the OSA pathway applies.
- Clinical denial: appeal with the missing documentation.
- Renewal denial: check whether the 5% (weight) or 10% (OSA) threshold was measured from your original starting weight.[1]
Paying if Cigna won’t cover it
With commercial insurance that excludes Zepbound, Lilly’s savings card can bring the single-dose pen to as low as $499 a month or the KwikPen to $299 to $449.[8] See Zepbound savings card, Zepbound cost without insurance and does insurance cover Zepbound?
